In agreement with previous studies, a prospective analysis of cytokine profile in 29 metastatic NSCLC patients receiving second line anti-PD1 monotherapy revealed that patients with higher IL-6 levels had a less durable response and significantly poorer PFS (5.14 vs. 38.57 weeks; p < 0.001) compared to patients with lower IL-6 levels [147]. This evidence concerns the gene IL6 and non-small cell lung carcinoma.